Clinical data and sequencing data from published studies were collected and consolidated to analyze the association between MGA mutation status and efficacy of ICI therapy in NSCLC and pan-cancers cohort respectively….In the pool NSCLC cohort (N = 262), significant differences were detected between MGA-MUT and MGA_WT patients regarding objective response rate (ORR, 52.2% vs 23.9%, p= 0.006), disease control rate (DCR,86.9% vs. 61.2%, p = 0.013), durable clinical benefit (DCB, 69.6% versus 36.7%, p= 0.003), and mPFS in MGA-MUT was 15.1 months much longer than 4.3 months in the MGA_WT (adjusted p=0.008).